hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06309472 id: NIHR302528 briefTitle: Trial of Mirtazapine for Depression in IBD acronym: MDIBD overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-02 date: 2026-06 date: 2024-03-13 date: 2024-03-13 name: King's College London class: OTHER name: King's College Hospital NHS Trust name: Imperial College London name: London North West Healthcare NHS Trust name: Imperial College Healthcare NHS Trust name: Guy's and St Thomas' NHS Foundation Trust briefSummary: This study will test whether it is feasible to conduct a clinical trial of mirtazapine (an antidepressant tablet) in patients who have both depression and inflammatory bowel disease (IBD). The study design is a randomised controlled trial (a study in which people are allocated by chance to receive different interventions). The trial will compare mirtazapine against a placebo (dummy) tablet in 76 patients with both depression and IBD.
The investigators will recruit outpatients aged 18 or over with a diagnosis of any IBD attending gastroenterology clinics. Either in person or remotely, patients will complete a brief screening questionnaire for depression. Those scoring positive for depression will be invited for a 15-minute interview for clinical depression. Those with clinical depression will be invited to take part. Participants will be randomly allocated by a computer to take either 1) mirtazapine tablet once at night for 12 weeks; or 2) placebo (dummy) tablet once at night for 12 weeks. The study is 'blinded', meaning neither patients nor the study team will know which medication they are taking. Throughout, participants will be able to access other treatments for depression, such as talking therapies.
If successful, this trial will support an application for a larger version of the study. conditions: Major Depressive Disorder conditions: Inflammatory Bowel Diseases studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Mirtazapine and placebo manufactured to appear identical through over-encapsulation whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 76 type: ESTIMATED name: Mirtazapine name: Placebo measure: Recruitment feasibility measure: Trial adherence measure: Treatment adherence measure: Study procedures acceptability and compliance measure: Overall acceptability measure: Quick Inventory for Depressive Symptomatology-16 Questionnaire measure: Patient Health Questionnaire-9 questionnaire measure: Generalised Anxiety Disorder-7 questionnaire measure: Inflammatory Bowel Disease Control questionnaire measure: Inflammatory Bowel Disease Fatigue Assessment Scale measure: Chalder Fatigue Scale measure: Maudsley 3-item Visual Analogue Scale measure: Pittsburgh Sleep Quality Index measure: 9-item Avoidant Restrictive Food Intake Disorder Screen measure: Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) Questionnaire measure: Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ) items on employment and healthcare contacts measure: Birmingham Irritable Bowel Syndrome Symptoms Questionnaire measure: Harvey Bradshaw Index (Crohn's disease patients only) measure: Simple Clinical Colitis Activity Index (ulcerative colitis patients only) measure: Dietary Screener Questionnaire measure: Concentration of faecal calprotectin measure: Concentration of serum high-sensitivity C-reactive protein measure: Concentration of serum interleukin-23 measure: Concentration of serum interleukin-22 measure: Concentration of serum granulocyte-macrophage colony-stimulating factor measure: Concentration of serum interleukin-5 measure: Concentration of serum interleukin-13 measure: Concentration of serum interleukin-17A measure: Concentration of serum tumor necrosis factor alpha measure: Concentration of serum interferon-gamma sex: ALL minimumAge: 18 Years maximumAge: 125 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06309459 id: IRB 2023/04-34 briefTitle: Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma overallStatus: COMPLETED date: 2018-08-01 date: 2023-05-01 date: 2023-05-01 date: 2024-03-13 date: 2024-03-13 name: Kahramanmaras Sutcu Imam University class: OTHER briefSummary: Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect. conditions: Triple Negative Breast Cancer conditions: Carbonic Anhydrase IX studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: Carbonic anhydrase staining levels measure: Poor prognostic factors in patients with TNBC measure: The treatment success with inhibiting the CA IX enzyme levels' effectiveness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kahramanmaraş Sütçü İmam University city: Kahramanmaraş zip: 46000 country: Turkey lat: 37.5847 lon: 36.92641 hasResults: False
nctId: NCT06309446 id: 381001BS briefTitle: Assessment of Wound Healing, Cooling Efficacy and Local Tolerability of a Wound Care Hydrogel overallStatus: COMPLETED date: 2020-01-14 date: 2020-02-19 date: 2020-07-02 date: 2024-03-13 date: 2024-03-13 name: Oystershell NV class: INDUSTRY name: Bioskin GmbH briefSummary: Test the wound healing properties of the product as well as the cooling effect and tolerability of a wound care gel. conditions: Wound studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 33 type: ACTUAL name: Zoralan Wound measure: Wound healing efficacy (clinical) measure: Wound healing efficacy (global) measure: Cooling properties measure: Local tolerability (clinical) measure: Local tolerability (global) measure: Signs of infection measure: Time until 100% healing measure: Time until 75% healing measure: Presence of crusts measure: Questionnaire on product performance measure: Cosmetic outcome/acceptance measure: Photographic documentation of the wound - visual of the wound to support previous outcomes. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bioskin GmbH city: Hamburg zip: 20095 country: Germany lat: 53.57532 lon: 10.01534 hasResults: False
nctId: NCT06309433 id: DXA-TKA briefTitle: Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design acronym: DXA-TKA overallStatus: RECRUITING date: 2023-08-30 date: 2027-12 date: 2028-04 date: 2024-03-13 date: 2024-03-13 name: Istituto Ortopedico Rizzoli class: OTHER briefSummary: compare changes in BMD via DXA at the level of the femoral and tibial periprosthetic bone between two groups of patients undergoing cemented TKA of different design (posterior stabilization vs posterior cruciate preservation) with proms at a 2-year follow-up. conditions: Periprosthetic Osteolysis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: dual energy x-ray absorptiometry measure: Periprosthetic bone mineral density measurement measure: Periprosthetic bone mineral density measurement measure: Periprosthetic bone mineral density measurement measure: Periprosthetic bone mineral density measurement measure: Knee Society Score measure: Knee Society Score measure: Knee Society Score measure: Knee Society Score measure: Western Ontario and McMaster Universities Arthritis Index measure: Western Ontario and McMaster Universities Arthritis Index measure: Western Ontario and McMaster Universities Arthritis Index measure: Western Ontario and McMaster Universities Arthritis Index measure: Knee injury and Osteoarthritis Outcome Score measure: Knee injury and Osteoarthritis Outcome Score measure: Knee injury and Osteoarthritis Outcome Score measure: Knee injury and Osteoarthritis Outcome Score measure: 36-Item Short Form Health Survey measure: 36-Item Short Form Health Survey measure: 36-Item Short Form Health Survey measure: 36-Item Short Form Health Survey sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stefano Zaffagnini status: RECRUITING city: Bologna state: Italia country: Italy name: Stefano Zaffagnini, MD role: CONTACT phone: 051 6366075 email: stefano.zaffagnini@unibo.it lat: 44.49381 lon: 11.33875 facility: Istituto ortoepdico rizzoli status: RECRUITING city: Bologna zip: 40136 country: Italy name: Stefano Zaffagnini, Prof. role: CONTACT phone: 00390516366111 email: stefano.zaffagnini@unibo.it lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06309420 id: 19E0566 briefTitle: Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts overallStatus: COMPLETED date: 2019-11-07 date: 2020-08-10 date: 2020-08-10 date: 2024-03-13 date: 2024-03-13 name: Oystershell NV class: INDUSTRY briefSummary: The present study was set-up to evaluate clinical efficacy of Pixie CO2 versus a comparator product (Wortie®) for the treatment of common and plantar warts. conditions: Warts studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Investigator-blinded, Randomized,Tested product versus comparator (benchmark product), In parallel groups, With multiple applications, Single centre. primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 54 type: ACTUAL name: Cryogenic treatment of warts (Pixie CO2) name: Cryogenic treatment of warts (Wortie®) measure: Percentage of subjects with clinical wart remission measure: Number of treatments measure: Efficacy of the freezing process (Surface Area) measure: Diameter of the wart measure: Roughness of the wart measure: Thickness of the wart (For common warts only) measure: Presence of small dark spot (For plantar warts only) measure: Healing process of the wart measure: Local & general tolerance sex: ALL minimumAge: 4 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Dermscan Poland city: Gdansk zip: 80-288 country: Poland lat: 54.35205 lon: 18.64637 hasResults: False
nctId: NCT06309407 id: STUDY00024903 briefTitle: Dosimeter Location in Pain Physicians overallStatus: COMPLETED date: 2022-09-23 date: 2023-04-21 date: 2023-04-21 date: 2024-03-13 date: 2024-03-13 name: Oregon Health and Science University class: OTHER briefSummary: The primary objective is to determine if there is a significant difference in radiation readings between dosimeters worn on the chest versus the hand of interventional pain management physicians and elucidate which dosimeter had higher readings.
The secondary objective is to track incidences of physician glove breaches in both groups to assess if wearing hand dosimeters is associated with an increased risk of this event. conditions: RAD studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants were randomized to wear either chest dosimeters only or chest and hand dosimeters for the duration of the study in order to measure differences in radiation readings by each dosimeter location. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 10 type: ACTUAL name: Hand Dosimeters name: Standard Practice measure: Radiation Readings measure: Number of Glove Breach Events sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Oregon Health & Science University city: Portland state: Oregon zip: 97239 country: United States lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06309394 id: INCB99280-102 briefTitle: A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-06-03 date: 2024-06-03 date: 2024-03-13 date: 2024-03-13 name: Incyte Corporation class: INDUSTRY briefSummary: This study is being conducted to assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]INCB099280 in Healthy Male Participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 7 type: ESTIMATED name: INCB099280 measure: Total recovery of radioactivity from urine and feces. measure: Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion measure: Pharmacokinetic (PK) in Plasma measure: PK for whole blood and plasma total radioactivity measure: Number of participants with Treatment Emergent Adverse Events (TEAEs) sex: MALE minimumAge: 35 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06309381 id: CEIm2.23 briefTitle: Influence of Sensory Block Duration on Rebound Pain After Outpatient Foot Surgery Under Popliteal Sciatic Nerve Block. overallStatus: RECRUITING date: 2023-02-08 date: 2024-10 date: 2024-10 date: 2024-03-13 date: 2024-03-13 name: Hospital Universitario Doctor Peset class: OTHER briefSummary: Rebound pain after surgeries under peripheral nerve block is defined as the appearance of severe acute postoperative pain after regression of the sensory block. The incidence of this condition can reach up to 40-50% in patients undergoing ambulatory surgeries. Rebound pain represents a clinically significant issue that may outweigh the benefits of regional anaesthesia. This is particularly significant for painful outpatient surgeries, where inadequately managed pain can result in distress, potentially affecting patient satisfaction and recovery. It may also lead to unplanned utilization of healthcare resources or readmissions.
Orthopaedic foot surgery is a prevalent outpatient surgery, potentially painful, where rebound may be a difficult challenge. However, to date, prospective studies focusing specifically on rebound pain in outpatient foot surgery are limited. Identifying conditions associated with rebound pain or at-risk patients could facilitate the development of preventive and treatment strategies, thereby enhancing pain management or relief. Younger age, female sex and bone surgery are non-modifiable factors associated with severe rebound pain. Perioperative intravenous dexamethasone has been identified as a modifiable independent risk factor associated with a reduced incidence of rebound pain. Regarding anaesthetic factors, the duration of the peripheral block has been proposed as a potentially modifiable factor influencing rebound pain; however, current evidence does not support this hypothesis.
The goal of this prospective observational study is to evaluate the incidence of rebound pain specifically in outpatient orthopaedic foot surgery involving bone under popliteal sciatic nerve block and to assess the possible association between sensory block duration and the incidence of rebound pain. conditions: Rebound Pain conditions: Sciatic Nerve Block conditions: Foot Surgery conditions: Outpatient Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Incidence of rebound pain. measure: Sensory block duration of the sciatic nerve block. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Av. de Gaspar Aguilar, 90 status: RECRUITING city: Valencia zip: 46017 country: Spain name: Javier Barrio, MD, PhD role: CONTACT phone: 0034646819882 email: jbarrio.ma@gmail.com name: Javier Barrio, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06309368 id: 003875 briefTitle: Ostomy Primary Closure With 0.1% Betaine/0.1% Polyhexanide Wound Irrigation Compared to Pursestring Closure overallStatus: RECRUITING date: 2024-03-14 date: 2024-12 date: 2025-12 date: 2024-03-13 date: 2024-03-25 name: University of Nevada, Las Vegas class: OTHER briefSummary: The goal of this clinical trial is to compare two types of closure in patients with ostomies that are ready for closure. The main questions it aims to answer are:
Participants will undergo either complete ostomy wound closure after washing out the wound with Prontosan, or their ostomy wound will be closed using the Pursestring method, where the wound will be left partially open and allowed to heal from the inside out. Researchers will compare these two groups' outcomes (questions to be answered) as listed above. conditions: Surgical Site Infection conditions: Wound Surgical conditions: Colorectal Disorders studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly assigned to one of the two treatment groups. primaryPurpose: TREATMENT masking: NONE maskingDescription: No masking. This is a non-blinded randomized controlled trial count: 84 type: ESTIMATED name: Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation name: Pursestring Closure measure: Surgical Site Infection Rates measure: Acceptability of wound and scar healing by patient measure: Acceptability of wound and scar healing by patient measure: Acceptability of wound and scar healing by patient measure: Acceptability of wound and scar healing by patient measure: Wound healing sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Medical Center status: RECRUITING city: Las Vegas state: Nevada zip: 89102 country: United States name: Abigail W Cheng, MD role: CONTACT phone: 916-695-4159 email: abigail.cheng@unlv.edu name: Lance Horner, MD role: CONTACT phone: 7755445456 email: lance.horner@unlv.edu name: Ovunc Bardakcioglu, MD role: PRINCIPAL_INVESTIGATOR name: Lance Horner, MD role: PRINCIPAL_INVESTIGATOR name: Abigail W Cheng, MD role: SUB_INVESTIGATOR name: Henry Krasner, BS role: SUB_INVESTIGATOR name: Kavita Batra, PhD role: SUB_INVESTIGATOR lat: 36.17497 lon: -115.13722 hasResults: False
nctId: NCT06309355 id: YR001-A03 briefTitle: Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-01 date: 2025-06 date: 2024-03-13 date: 2024-03-18 name: Hangzhou Yirui Pharmaceutical Technology Co., Ltd class: INDUSTRY briefSummary: This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 36 type: ESTIMATED name: YR001 ointment name: Placebo measure: The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50. measure: all treatment-emergents AEs measure: Efficacy of YR001 Ointment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: DelRicht Research city: Baton Rouge state: Louisiana zip: 70809 country: United States name: Ira H Thorla, Doctor role: CONTACT lat: 30.45075 lon: -91.15455 hasResults: False
nctId: NCT06309329 id: 1770023-2 briefTitle: Strength at Home - Parents RCT overallStatus: ENROLLING_BY_INVITATION date: 2024-03-30 date: 2029-05 date: 2029-05 date: 2024-03-13 date: 2024-04-24 name: VISN 17 Center of Excellence class: FED name: United States Department of Defense name: University of Texas at Austin briefSummary: The goal of this clinical trial is to compare the effect of the Strength at Home Parents intervention to treatment as usual in veterans enrolled for care at VA facilities in VISN 17 on parenting stress and parenting behaviors. The participant population will have elevated PTSD symptoms and parent-child functioning difficulties with an index child between the ages of 3-12. The main question\[s\]it aims to answer are: • Does Strength at Home Parents improve parenting stress and parenting behaviors in comparison to a no-treatment control condition? • Are gains maintained over time and is there a gender difference in efficacy? Participants will complete 4 online assessments, and if randomized to the intervention group they will complete an 8 week tele-health group program. If randomized to the control group participants will receive a link to the VA parenting resources website and any referrals they would like to have. Researchers will compare Strength at Home Parents to VA treatment as usual see if the group intervention improves parenting stress and behaviors above and beyond the existing resources. conditions: Parent-Child Relations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Strength at Home Parents name: VA treatment as usual measure: Parenting Stress Index total score measure: Parenting Stress Index total score measure: Parenting Stress Index total score measure: Laxness subscale on the Parenting Scale measure: Laxness subscale on the Parenting Scale measure: Laxness subscale on the Parenting Scale measure: Over reactivity subscale on the Parenting scale measure: Over reactivity subscale on the Parenting scale measure: Over reactivity subscale on the Parenting scale measure: PTSD Symptom Checklist score measure: PTSD Symptom Checklist score measure: PTSD Symptom Checklist score measure: Quick Inventory of Depressive Symptoms measure: Quick Inventory of Depressive Symptoms measure: Quick Inventory of Depressive Symptoms measure: Total Family Problems Score measure: Total Family Problems Score measure: Total Family Problems Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Central Texas Veterans Healthcare System city: Temple state: Texas zip: 76504 country: United States lat: 31.09823 lon: -97.34278 hasResults: False
nctId: NCT06309316 id: Grace-PCC briefTitle: The Impact of Person Centred Care (PCC) in Grave's Disease overallStatus: RECRUITING date: 2024-03-25 date: 2027-09-30 date: 2028-12-30 date: 2024-03-13 date: 2024-04-26 name: Vastra Gotaland Region class: OTHER_GOV briefSummary: Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after successfully reversing of their hyperthyroidism and that MF is an entity of its own, separated from MF combined with anxiety or depression. The brain pathophysiology is unknown and there is no medical treatment, which requires patients to simply adapt to the situation. In the new national guideline for hyperthyroidism (Jan 2023), rehabilitation is recommended, but currently rarely offered to these patients. The problem is significant for patients, as illustrated by frequent media appeals. In this project, we hypothesise that person-centred care (PCC), which promotes positive coping strategies and increases self-efficacy by engaging patients as partners in their own care, improves MF, reduces sick leave, and lowers the recurrence rate of GD. In two work packages (WP), we will: